news

Latest News

View All

Personal Genome Diagnostics Awarded Department of Veterans Affairs Contract for Its PlasmaSELECT™ Liquid Biopsy Cancer Profiling Assay

–PGDx’s PlasmaSELECT 64 Panel Is the First Non-Invasive Liquid Biopsy Assay Available to Cancer Patients Treated at VA Facilities––Targets 64 Well-Characterized Cancer Genes and Is the Only Liquid Biopsy Panel that Includes Testing for Microsatellite Instability (MSI) for Use in Immuno-oncology Applications–BALTIMORE, June 14, 2017 /PRNewswire/ — Personal Genome Diagnostics Inc. (PGDx) today announced an…

Personal Genome Diagnostics’ new kind of cancer test is going to be used by the VA

Personal Genome Diagnostics (PGDx) received a new contract from the U.S. Department of Veterans Affairs to provide a test for cancer that does not require tissue samples.The Canton-based company makes a liquid biopsy, which tests for cancer by evaluating 64 genes that are associated with cancer.The test can be conducted through a blood test, rather…

PGDx Expands Veterans Affairs Agreement to Include Liquid Biopsy Testing

NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that it will now provide its PlasmaSelect 64 liquid biopsy test to advanced cancer patients receiving treatment at US Department of Veterans Affairs facilities.The agreement makes PGDx the first to provide plasma-based genomic profiling to VA cancer patients, expanding on an existing contract under which…